Tirzepatide vs Retatrutide
Dual agonist vs triple agonist — the next frontier of GLP-1 weight loss therapy. SURMOUNT vs TRIUMPH clinical trial data compared.
💊 Tirzepatide
- Brand Names
Mounjaro, Zepbound - Mechanism
Dual GLP-1/GIP agonist - Max Weight Loss
22.5% (SURMOUNT-1) - FDA Status
✅ Approved (T2D 2022, Obesity 2023) - Manufacturer
Eli Lilly - Key Trial
SURMOUNT program (N=2,539) - Dosing
Weekly injection, 2.5–15 mg - Cost
$1,000–$1,200/mo (cash)
🧪 Retatrutide
- Brand Names
LY3437943 (investigational) - Mechanism
Triple GLP-1/GIP/Glucagon agonist - Max Weight Loss
24.2% (Phase 2, 12mg/48wk) - FDA Status
❌ Not approved (Phase 3) - Manufacturer
Eli Lilly - Key Trial
TRIUMPH program - Dosing
Weekly injection (dose TBD) - Cost
Not yet available commercially
Mechanism of Action
Tirzepatide — The Dual Agonist
Tirzepatide activates two receptors simultaneously:
- GLP-1 receptor: Reduces appetite, slows gastric emptying, enhances insulin secretion
- GIP receptor: Improves insulin sensitivity, enhances fat metabolism in adipose tissue
Retatrutide — The Triple Agonist
Retatrutide adds a third target to the dual-agonist approach:
- GLP-1 receptor: Same appetite and insulin benefits as tirzepatide
- GIP receptor: Same metabolic and insulin sensitivity benefits
- Glucagon receptor: Increases energy expenditure, promotes hepatic fat oxidation, enhances thermogenesis
💡 Why Does the Third Receptor Matter?
Think of it this way: tirzepatide reduces calorie intake (GLP-1) and improves how your body processes those calories (GIP). Retatrutide does both of those plus actively burns more calories through glucagon-mediated energy expenditure. It's the difference between eating less and eating less while your metabolism runs hotter.
Weight Loss Efficacy
Head-to-head comparison of maximum weight loss achieved in respective clinical trial programs:
⚠️ Cross-Trial Comparison Caveat
These numbers come from separate clinical trials with different patient populations, inclusion criteria, and timeframes. Direct comparison requires a head-to-head trial, which has not been conducted between tirzepatide and retatrutide. The data is directionally informative but not statistically equivalent to a head-to-head comparison.
Side Effect Comparison
Both share the GI side effect profile common to GLP-1 agonists. Retatrutide's glucagon component introduces some unique considerations:
⚖️ Who Should Choose What?
- You want a proven, FDA-approved medication available now
- You have type 2 diabetes (approved for both T2D and obesity)
- Your insurance covers Mounjaro or Zepbound
- You prefer a medication with an established multi-year safety record
- You've plateaued on semaglutide and want to upgrade
- You want maximum possible weight loss (its Phase 2 data is the most promising in class; Phase 3 ongoing)
- You have significant fatty liver disease (glucagon receptor may specifically help)
- You've plateaued on tirzepatide and need something more potent
- You're willing to wait for FDA approval (expected 2026–2027)
Tirzepatide is the proven choice available today. Retatrutide is the next evolution, showing even greater weight loss in trials, but isn't yet approved. If you need treatment now, tirzepatide is excellent. If you can wait, retatrutide may set a new standard — both are from Eli Lilly, so the transition should be seamless when the time comes.
Frequently Asked Questions
Tirzepatide is a dual GLP-1/GIP receptor agonist, while retatrutide is a triple GLP-1/GIP/glucagon receptor agonist. Retatrutide adds glucagon receptor activation, which increases energy expenditure and fat burning beyond what tirzepatide achieves.
In clinical trials, tirzepatide showed 22.5% mean weight loss (SURMOUNT-1, 72 weeks). Retatrutide showed 24.2% mean weight loss at 12mg over 48 weeks in its Phase 2 trial (Jastreboff et al., NEJM 2023, PMID 37366315); its Phase 3 TRIUMPH topline is still pending. These are from different trials and not directly comparable.
No, retatrutide is not yet FDA-approved as of 2026. It is in Phase 3 clinical trials (TRIUMPH program) by Eli Lilly. Tirzepatide (Mounjaro/Zepbound) is FDA-approved for T2D and obesity.
Glucagon receptor activation increases energy expenditure, promotes liver fat burning, and enhances thermogenesis. This third mechanism is what differentiates retatrutide from tirzepatide and likely drives the greater weight loss.
It's too early to say definitively. Both are made by Eli Lilly and may serve different segments — tirzepatide for standard treatment and retatrutide for patients needing maximum weight loss. They'll likely coexist.
Both share GI side effects (nausea, diarrhea, vomiting). Retatrutide's glucagon component may cause slightly elevated heart rate. Tirzepatide has a more established safety profile with years of post-market data.
🛒 Recommended Products
Products commonly used alongside GLP-1 weight loss therapy
Affiliate links help support HighPeptides at no extra cost to you.
Related Comparisons & Tools
Explore more weight loss peptide resources